Keyphrases
17q12 Deletion Syndrome
12%
Adjusted Hazard Ratio
7%
Autoimmune Disease
12%
Bionic Pancreas
24%
Cardiovascular Outcomes
12%
Care Groups
8%
Comparative Effectiveness Studies
24%
Composite Outcome
12%
Continuous Glucose Monitoring
35%
Control Body
12%
Diabetes
15%
Glimepiride
9%
Glucose Level
7%
Glycated Hemoglobin Levels
5%
Glycemia
24%
Glycemic Control
24%
Heart Failure Hospitalization
7%
Hemoglobin A1c (HbA1c)
23%
High Prevalence
12%
Hypoglycemia
52%
Insulin
14%
Insulin Aspart
5%
Insulin Lispro
5%
Insulin Receptor
6%
Insulin Receptor Antibody
12%
Late-onset
12%
Liraglutide
17%
Male Hypogonadism
12%
Maturity-onset Diabetes of the Young type 5
12%
Median Time
7%
Mixed Connective Tissue Disease
12%
Multicenter Randomized Trial
24%
Old Age
12%
Older Adults
24%
Older Women
6%
Ovarian Cancer
5%
Plasma Glucose
10%
Reduction Approach
24%
Rheumatic Diseases
12%
Second-line Therapy
12%
Serous Ovarian Carcinoma
12%
Severe Hypoglycemia
10%
Sitagliptin
8%
Standard of Care
6%
Treatment Group
9%
Type 1 Diabetes Mellitus (T1DM)
100%
Type 2 Diabetes Mellitus (T2DM)
37%
Type I Diabetes
73%
Weight Gain
7%
Wireless
13%
Medicine and Dentistry
Acetone
6%
Autoantibodies
12%
Autoimmune Disease
12%
Awareness
6%
Blood Glucose Monitoring
12%
Body Weight
14%
Breathing
12%
Cardiovascular Disease
9%
Cardiovascular System
12%
Care Group
8%
Congestive Heart Failure
7%
Dapagliflozin
12%
Deterioration
6%
Diabetes
18%
Diabetes Mellitus
28%
Effectiveness Study
24%
Glimepiride
11%
Glycated Hemoglobin
5%
Glycemic
8%
Glycemic Control
24%
Hazard Ratio
7%
Hemoglobin A1c
15%
Hydroxybutyric Acid
9%
Hypoglycemia
54%
Hypogonadism
12%
Insulin Aspart
5%
Insulin Dependent Diabetes Mellitus
62%
Insulin Lispro
5%
Insulin Receptor
12%
Krukenberg Tumor
12%
Liraglutide
18%
Maturity Onset Diabetes of the Young
37%
Mixed Connective Tissue Disease
12%
Niacin
24%
Ovarian Cancer
7%
Prevalence
5%
Randomized Clinical Trial
10%
Sitagliptin
9%
Treatment Group
9%
Type 1 Diabetes
14%